Development of a diagnostic instrument to manage hemostasis in chronic liver dise
Company: HemoSonics, LLC Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1Abstract: DESCRIPTION (provided by applicant): The clinical evaluation and management of hemostasis in the 5 million patients affected by chronic liver diseases (CLD) is poorly understood. Data presented at two International Symposia on Coagulation in Liver Disease
and summarized in a recent edition of… more
Development of a point of care diagnostic to guide efficient usage of blood produ
Company: HemoSonics, LLC Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1Abstract: DESCRIPTION (provided by applicant): Over 60% of the 600,000 patients undergoing cardio-pulmonary bypass (CPB) procedures in the US each year experience intra- and post-operative bleeding. Treatment options are available, each corresponding to a specific h
emostatic defect: (a) fresh frozen plasma… more
Second Generation Companion Mics System
Company: Etymotic Research, Inc. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1Abstract: DESCRIPTION (provided by applicant): Approximately 10 percent of hearing aid wearers have 10 dB loss of ability to understand speech in noise, in the sense that they require a signal-to-noise ratio 10 dB better than normal-hearing listeners. Since at m
any restaurants and social gatherings the… more
The Development of Immune-based Therapies Using Plant Derived Compounds to Attenu
Company: GOLDEN SOY, LLC Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1Abstract: DESCRIPTION (provided by applicant): Secondary metabolites will be extracted from a specific plant material to identify and isolate immune active components. These components are proposed to enhance the innate and adaptive immune systems by modulating cert
ain cytokine levels in white blood cells… more
Not Available
Company: STC BIOLOGICS, INC Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1Abstract: The goal of this project is to develop STC trastuzumab, a generic version of Herceptin. Trastuzumab is a monoclonal antibody made against the HER2 protein that is overexpressed in 20-25% of patients with breast cancer. Because of very high cost associated with prescribing Herceptin, a generic… more
Fitness Games Product Development Platform
Company: HEARTRATE GAMES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1Abstract: DESCRIPTION (provided by applicant): HeartRate Games' objective is to speed the pace of fitness games innovation by giving developers a set of technology tools that make it easier to create great products combining fitness games with the proven benefits of
cardio exercise machines. Fitness games… more
Starch-Entrapped Microspheres [Nutrabiotix Fiber] for Gut Health
Company: NUTRABIOTIX, LLC Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1Abstract: DESCRIPTION (provided by applicant): To establish the proof of concept that Nutrabiotix fiber is safe and well tolerated, promotes gut health by increasing production of short chain fatty acids and changes colonic microbiota composition in favor of bifidob
acteria, improves bowel habit and increase… more
Ototoxicity protection with intratympanic steroid implant
Company: O-RAY PHARMA, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1Abstract: DESCRIPTION (provided by applicant): Chemotherapy-induced ototoxicity is damage to the inner ear that is caused by the side effects of administered drugs. This can lead to permanent hearing loss and/or tinnitus (continuous ringing in the ear) in the patient. Some of the most common kinds of drugs… more
CIRCULATING TUMOR CELL ENUMERATION PRODUCT
Company: EPIC SCIENCES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1Abstract: 'This project was funded as a Phase I contract by the NCI Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Program in response to funding announcement number 272 "Point of Care Analysis of Circulating Tumor Cells for Cancer Diagnostics, Prognosis, and… more
To demonstrate the feasibility of a home tonometer to monitor IOP without contact
Company: ACHEVE TECHNOLOGY, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1Abstract: DESCRIPTION (provided by applicant): This research is to study the feasibility of an in-home tonometer based on the two color strobe technology (TCST) developed by CeeMaxTM Ophthalmic, a division of Achevi Technology. We are the manufacturer of ophthalmic
diagnostic instruments with core expertise… more
Human Variation Detection and Visualization on the DNAnexus Web 2.0 platform
Company: DNANEXUS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1Abstract: DESCRIPTION (provided by applicant): DNAnexus proposes to develop a complete solution for the identification and stratification of personal genetic variation from ultra-high-throughput sequencing projects. The solution will be implemented as a Web 2.0 serv
ice and online browsing tool that will… more
Feasibility of a Web-based Collaborative Care Support(SM)Model to Improve Care fo
Company: LONGITUDE HEALTH, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1Abstract: DESCRIPTION (provided by applicant): Diabetes costs the United States an estimated 174 billion annually. About two-thirds of costs arise from direct medical expenditures, and the remainder accrues from disability, work loss, and premature mortality. Assoc
iated cardiovascular comorbidities result… more
Millikan Sequencing by Label-Free Detection of Nucleotide Incorporation
Company: CAERUS MOLECULAR DIAGNOSTICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1Abstract: DESCRIPTION (provided by applicant): The feasibility of a label-free technology, Millikan Sequencing, will be evaluated for de novo sequencing of mammalian genomes for under 1,000. This novel sequencing-by-synthesis approach measures the increased charg
e as nucleotides are added to DNA templates… more
Gastric Sleeve Magnetic Implant
Company: 3DT HOLDINGS, LLC Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1Abstract: DESCRIPTION (provided by applicant): The occurrence of obesity is increasingly growing, and it has been projected that 40% of the US population will be obese by the year 2025. The World Health Organization estimates over 1.6 billion adults (age 15+) are ov
erweight, and at least 400 million are… more
Expanding Precision Particle Fabrication Technology for the Widespread Control of
Company: ORBIS BIOSCIENCES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1Abstract: DESCRIPTION (provided by applicant): This overall goal of this project is to develop a scalable process for fabricating oil encapsulated particles with uniform sizes and physical characteristics that contain oil as a vehicle for delivering hydrophobic drug
s. Poorly water soluble active… more
Multi-day Pain Management Therapy with Novel Injectable Formulation
Company: ORBIS BIOSCIENCES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2011 / 1Abstract: DESCRIPTION (provided by applicant): Our long term goal is to widespread the use of PPF technology for promoting effective production of drug-encapsulating microparticles with uniform size and physical characteristics that can be leveraged to release a specific drug at controlled rates over… more
Precision Particle Fabrication-enabled Betamethasone-loaded Microspheres for Tran
Company: ORBIS BIOSCIENCES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1Abstract: DESCRIPTION (provided by applicant): Current approaches to treat sudden sensorineural hearing loss (SSNHL) do not maintain inner ear drug concentrations within an appropriate therapeutic window for sufficient lengths of time to achieve therapeutic effect.A novel delivery system for long-term,… more
Engineering Microparticles for Taste-Masking and Controlled Release of Pediatric
Company: ORBIS BIOSCIENCES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1Abstract: DESCRIPTION (provided by applicant): Pediatric drug development presents many unique challenges in the effective treatment of diseases in children, from adequate dosing information and pediatric-specific testing to palatable flavor profiles and effective delivery formats. A novel technology that… more
Hemostatic-antibiotic Combination for Prevention of MRSA Surgical Site Infections
Company: CEREMED, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1Abstract: DESCRIPTION (provided by applicant): Ostene is a soft, synthetic, moldable hemostatic material that sticks well to cut bone surfaces and stops bleeding by mechanical occlusion. Ostene is a combination of biocompatible water-soluble polymers which are absor
bed completely within 24 to 48 hours of… more
Discovery and Development of Novel Glucose Dependent Partial Glucokinase Activato
Company: CALASIA PHARMACEUTICALS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1Abstract: DESCRIPTION (provided by applicant): Type 2 diabetes (T2DM) is a chronic metabolic disease that affects the quality and longevity of life. Currently it is estimated that about 246 million people worldwide and diabetic and their number is expected to increa
se to 380 million by 2025. Further, the… more
Selective and dual-acting Hsp90 and TRAP1 inhibitors
Company: CALASIA PHARMACEUTICALS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1Abstract: DESCRIPTION (provided by applicant): Although the existing agents for treating cancer have shown promising results, the inherent genetic plasticity of the cancer cells continues to undermine the efficacy of these treatments. One of the possible solutions t
o address this problem is to attack the… more
Microfluidic DNA Sequencing
Company: GNUBIO, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1Abstract: DESCRIPTION (provided by applicant): Most next-generation DNA sequencing methods have focused on either 1) template amplification followed by massively-parallel sequencing-by-synthesis, or 2) single molecule detection. The first method is now commercially
available but suffers from relatively… more
Compact System for Dynamic Nuclear Polarization Enhanced 600 MHz Solid-State NMR
Company: BRIDGE 12 TECHNOLOGIES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1Abstract: DESCRIPTION (provided by applicant): The proposed research is directed at designing and demonstrating a compact, cost-effective high-frequency, tunable 2nd-harmonic gyrotron for Dynamic Nuclear Polarization (DNP) enhanced solid-state Nuclear Magnetic Reson
ance (SSNMR) spectroscopy at 600 MHz. With… more
Recombinant antigen diagnostics for filoviruses
Company: CORGENIX MEDICAL CORPORATION Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1Abstract: DESCRIPTION (provided by applicant): Viral hemorrhagic fevers (VHFs) are serious, often fatal, illnesses characterized by high fever, damage to the vascular system and multiorgan failure. Our team has successfully produced prototype Lassa virus ELISA that
are based on recombinant proteins rather… more
VLP-Based Antibody-Inducing Vaccines for HIV-1
Company: ALTRAVAX, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1Abstract: DESCRIPTION (provided by applicant): The HIV-1 epidemic has resulted in ~2.7 million new infections in 2007 for a total of ~33 million people living with HIV/AIDS. Clinical trials have shown that HIV-1 infection cannot be prevented by immunization with mon
omeric recombinant forms of viral envelope… more